Suchergebnisse - "Dexamethasone"

PubPharm (140.414)

91

Locally released dexamethasone and its effects on osteogenic activity at implant-tissue interface

enthalten in: Journal of biomedical materials research. Part A | 2024

von Kerem, G. | Önder, S. | Kılıç, A.

92

TaoHe ChengQi decoction ameliorates sepsis-induced cardiac dysfunction through anti-ferroptosis via the Nrf2 pathway

enthalten in: Phytomedicine : international journal of phytotherapy and phytopharmacology | 2024

von Lu, S. | Yang, B. | Tan, Z. | +12

93

Differential role of glucocorticoid receptor based on its cell type specific expression on tumor cells and infiltrating lymphocytes

enthalten in: Translational oncology | 2024

von Snijesh, V. | Nimbalkar, V. | Patil, S. | +9

94

Efficacy and safety of metronomic cyclophosphamide combined with abiraterone and dexamethasone in heavily pretreated metastatic castration resistant prostate cancer：A retrospective, real-world study

enthalten in: Asian journal of surgery | 2024

von Zhang, L. | Zhou, L. | Shi, Y. | +1

95

Treatment of Noninfectious Uveitic Macular Edema with Periocular and Intraocular Corticosteroid Therapies : A Report by the American Academy of Ophthalmology

enthalten in: Ophthalmology | 2024

von Smith, J. | Thorne, J. | Flaxel, C. | +7

96

UHRF1 poly-auto-ubiquitination induced by the anti-cancer drug, thymoquinone, is involved in the DNA repair machinery recruitment

enthalten in: The international journal of biochemistry & cell biology | 2024

von Almalki, N. | Sabir, J. | Ibrahim, A. | +10

97

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma : A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

98

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial : Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)

enthalten in: ClinicalTrials.gov | 2024

99

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide : A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

enthalten in: ClinicalTrials.gov | 2024

100

Daratumumab for Patients With Light Chain Amyloidosis : Daratumumab and Dexamethasone Combined With Pomalidomide (DPD) or ASCT in the Treatment of Newly Diagnosed Systemic Light Chain Amyloidosis (AL Amyloidosis): a Prospective, Single Center Clinical Trial

enthalten in: ClinicalTrials.gov | 2024